Connection

ARGUN AKCAKANAT to Biomarkers, Tumor

This is a "connection" page, showing publications ARGUN AKCAKANAT has written about Biomarkers, Tumor.
Connection Strength

0.093
  1. First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. Breast Cancer Res. 2021 03 04; 23(1):29.
    View in: PubMed
    Score: 0.049
  2. Influence of biospecimen variables on proteomic biomarkers in breast cancer. Clin Cancer Res. 2014 Jul 15; 20(14):3870-83.
    View in: PubMed
    Score: 0.030
  3. SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. J Natl Cancer Inst. 2015 Mar; 107(3).
    View in: PubMed
    Score: 0.008
  4. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res. 2012 Mar 15; 18(6):1777-89.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.